Business ❯ Healthcare ❯ Pharmaceuticals

Vaccine Development

Moderna Bavarian Nordic Moderna Inc. Clinical Trials Funding Strategies Pricing Strategies Respiratory Vaccines mRNA Technology Acquisitions Gardasil Public Health Bavarian Nordic Vaccines Strategic Partnerships Acquisition Licensing Agreements AstraZeneca Next-Generation Medications Norovirus Vaccine Public Health Policy Patent Rights

FDA to Review Moderna’s Flu Shot as Shares Rally on Earnings Beat

The review sets a decision deadline of August 5, 2026, signaling progress in Moderna’s shift toward a seasonal vaccine strategy.

Sanofi to Buy Dynavax for $2.2 Billion in All-Cash Tender Offer

Moderna Trims 2025 Forecast as Q3 Loss Narrows and Revenue Beats

Moderna Cuts 10% of Global Workforce in Major Cost Overhaul

Sanofi Signs $1.15 Billion Deal to Acquire Vicebio’s Molecular Clamp Respiratory Vaccine Platform